Annemijn M. Algra

Annemijn M. Algra

Auto-generated profile, based on publicly available information

Annemijn M. Algra

Department of Neurology and Neurosurgery, UMC Utrecht Brain Center (W.M.S., L.J.K., H.B.v.d.W., A.M.A.), University Medical Center Utrecht, Utrecht University, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
AAAnnemijn M. Algra
Annemijn M. Algra
ALAntti Lindgren
Antti Lindgren
MVMervyn D. I. Vergouwen
Mervyn D. I. Vergouwen
JGJacoba P. Greving
Jacoba P. Greving
ISIrene C. van der Schaaf
Irene C. van der Schaaf
GRGabriel J. E. Rinkel
Gabriel J. E. Rinkel
The prevalence of saccular unruptured intracranial aneurysms (UIAs) in the general population is 3%.1 Owing to the rising availability and quality of brain imaging, the number of incidentally discovered UIAs is increasing.2,3 Many UIAs remain asymptomatic, but some rupture, causing subarachnoid hemorrhage (SAH). This is a subtype of stroke with a poor prognosis (a case-fatality rate of approximately 35%), often affecting relatively young patients (mean age, 60 years).4 Preventive treatment of UIAs, either by endovascular treatment (EVT) or neurosurgical treatment (NST), can decrease the risk of SAH, but both treatment modalities carry a risk of serious complications.5 Currently, the decision to treat UIAs is a balance of risk of rupture, risk of treatment complications, life expectancy, and level of patient anxiety. For estimations of the rupture risk, prediction models are available that provide absolute risks of rupture for the next 5 years based on a few easily available risk factors.6,7 Such robust data are lacking for the estimation of complication risk from UIA treatment.5,8 The best available evidence comes from meta-analyses published in 2012 and 2013 on the procedural morbidity and case-fatality risk of EVT and NST.9,10 However, since the publication of these reviews, there has been a further shift toward EVT as the predominant treatment modality, with an increasing variety of advanced endovascular methods being used, such as stent-assisted or balloon-assisted coiling, flow-diverting stents, and Woven EndoBridge (WEB) Aneurysm Embolization devices. In addition, previous meta-analyses did not focus on risk factors for complications apart from subgroup analyses. Our aim is to provide an overview of the recent literature on EVT and NST, with several new focuses. In addition to assessing the procedural 30-day clinical complication and case-fatality risks of both treatment modalities, we conducted a meta-analysis of the available risk factor data for clinical complications from both EVT and NST, and we separately assess the complication risk of advanced endovascular methods that were increasingly applied in clinical practice over the last few years.

4 November 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
WSWouter M. Sluis
Wouter M. Sluis
MLMarijke Linschoten
Marijke Linschoten
JBJulie E. Buijs
Julie E. Buijs
JBJ. Matthijs Biesbroek
J. Matthijs Biesbroek
HHHeleen M. Den Hertog
Heleen M. Den Hertog
WGWiek H. van Gilst
Wiek H. van Gilst
Background and Purpose: The frequency of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) varies in the current literature, and risk factors are unknown. We assessed the incidence, risk factors, and outcomes of acute ischemic stroke in hospitalized patients with COVID-19. Methods: We included patients with a laboratory-confirmed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) infection admitted in 16 Dutch hospitals participating in the international CAPACITY-COVID registry between March 1 and August 1, 2020. Patients were screened for the occurrence of acute ischemic stroke. We calculated the cumulative incidence of ischemic stroke and compared risk factors, cardiovascular complications, and in-hospital mortality in patients with and without ischemic stroke. Results: We included 2147 patients with COVID-19, of whom 586 (27.3%) needed treatment at an intensive care unit. Thirty-eight patients (1.8%) had an ischemic stroke. Patients with stroke were older but did not differ in sex or cardiovascular risk factors. Median time between the onset of COVID-19 symptoms and diagnosis of stroke was 2 weeks. The incidence of ischemic stroke was higher among patients who were treated at an intensive care unit (16/586; 2.7% versus nonintensive care unit, 22/1561; 1.4%; P =0.039). Pulmonary embolism was more common in patients with (8/38; 21.1%) than in those without stroke (160/2109; 7.6%; adjusted risk ratio, 2.08 [95% CI, 1.52–2.84]). Twenty-seven patients with ischemic stroke (71.1%) died during admission or were functionally dependent at discharge. Patients with ischemic stroke were at a higher risk of in-hospital mortality (adjusted risk ratio, 1.56 [95% CI, 1.13–2.15]) than patients without stroke. Conclusions: In this multicenter cohort study, the cumulative incidence of acute ischemic stroke in hospitalized patients with COVID-19 was ≈2%, with a higher risk in patients treated at an intensive care unit. The majority of stroke patients had a poor outcome. The association between ischemic stroke and pulmonary embolism warrants further investigation.

18 October 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
AAAnnemijn M. Algra
Annemijn M. Algra
JGJacoba P. Greving
Jacoba P. Greving
JWJordi de Winkel
Jordi de Winkel
AKArttu Kurtelius
Arttu Kurtelius
KLKamil Laban
Kamil Laban
MVMervyn D.I. Vergouwen
Mervyn D.I. Vergouwen
Objective: Preventive unruptured intracranial aneurysm occlusion can reduce the risk of subarachnoid hemorrhage, but both endovascular and microneurosurgical treatment carry a risk of serious complications. To improve individualized management decisions, we developed risk scores for complications of endovascular and microneurosurgical treatment based on easily retrievable patient, aneurysm, and treatment characteristics. Methods: For this multicenter cohort study, we combined individual patient data from unruptured intracranial aneurysm patients ≥18 years undergoing preventive endovascular treatment (standard, balloon-assisted or stent-assisted coiling, Woven EndoBridge-device, or flow-diverting stent) or microneurosurgical clipping at one of 10 participating centers from three continents between 2000-2018. The primary outcome was death from any cause or clinical deterioration from neurological complications ≤30 days. We selected predictors based on previous knowledge about relevant risk factors and predictor performance and studied the association between predictors and complications with logistic regression. We assessed model performance with calibration plots and concordance (c) statistics. Results: Of 1282 included patients, 94 (7.3%) had neurological symptoms that resolved <30 days, 140 (10.9%) had persisting neurological symptoms, and 6 died (0.5%)). At 30 days, 52 patients (4.1%) were dead or dependent. Predictors of procedural complications were: size of aneurysm, aneurysm location, familial subarachnoid hemorrhage, earlier atherosclerotic disease, treatment volume, endovascular modality (for endovascular treatment) or extra aneurysm configuration factors (for microneurosurgical treatment; branching artery from aneurysm neck or unfavorable dome-to-neck ratio), and age (acronym: SAFETEA). For endovascular treatment (n=752), the c-statistic was 0.72 (95%CI:0.67-0.77) and the absolute complication risk ranged from 3.2% (95%CI:1.6%-14.9%;≤1 point) to 33.1% (95%CI:25.4%-41.5%;≥6 points). For microneurosurgical treatment (n=530), the c-statistic was 0.72 (95%CI:0.67-0.77) and the complication risk ranged from 4.9% (95%CI:1.5%-14.9%;≤1 point) to 49.9% (95%CI:39.4%-60.6%;≥6 points). Conclusions: The SAFETEA risk scores for endovascular and microneurosurgical treatment are based on seven easily retrievable risk factors to predict the absolute risk of procedural complications in patients with unruptured intracranial aneurysms. The scores need external validation before the predicted risks can be properly used to support decision making in clinical practice.

1 March 2021 in Journal of the Neurological Sciences
Verified
Journal Article
Open access
LHLaurie J. Hollands
Laurie J. Hollands
MVMervyn D.I. Vergouwen
Mervyn D.I. Vergouwen
JGJacoba P. Greving
Jacoba P. Greving
MWMarieke J.H. Wermer
Marieke J.H. Wermer
GRGabriël J.E. Rinkel
Gabriël J.E. Rinkel
AAAnnemijn M. Algra
Annemijn M. Algra
In management decisions on saccular unruptured intracranial aneurysms (UIAs) the risk of rupture is an important factor. The PHASES score, introduced in 2014, provides absolute 5-year risks of rupture based on six easily retrievable patient and aneurysm characteristics. We assessed whether management decisions on UIAs changed after implementation of the PHASES score. We included all patients with UIAs who were referred to two Dutch tertiary referral centers for aneurysm care in the Netherlands (University Medical Center Utrecht (UMCU) and Leiden University Medical Center (LUMC)) between 2011 and 2017. Analyses were done on an aneurysm level. We calculated the overall proportion of UIAs with a decision to treat before and after PHASES implementation and studied the influence of age and center on post-implementation management changes. We included 623 patients with 803 UIAs. The proportion of UIAs with a decision to treat was 123/360 (34.2%) before and 117/443 (26.4%) after PHASES implementation (absolute risk difference: -7.8%; 95% CI: -14.1 to -1.4). The decision to treat was made at a higher median PHASES score after implementation (7 points (IQR 5;10) pre- versus 8 points (IQR 5;10) post-implementation; p = 0.14). The reduced proportion with a treatment decision after implementation was most pronounced in patients <50 years (-22.3%; 95% CI: -39.2 to -3.4) and was restricted to treatment decisions made at the UMCU (-10.6%; 95% CI: -18.5 to -2.5). Management of UIAs changed following implementation of the PHASES score, but the impact of PHASES implementation on treatment decisions differed across age subgroups and centers.

18 October 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
AAAnnemijn M. Algra
Annemijn M. Algra
JGJacoba P. Greving
Jacoba P. Greving
MWMarieke J.H. Wermer
Marieke J.H. Wermer
MWMarianne A.A. van Walderveen
Marianne A.A. van Walderveen
ISIrene C. van der Schaaf
Irene C. van der Schaaf
MVMervyn D.I. Vergouwen
Mervyn D.I. Vergouwen
Objective: In counselling patients with an unruptured intracranial aneurysm (UIA), quality-of-life (QoL) outcomes are important for informed decision-making. We evaluated QoL outcomes in patients with and without preventive aneurysm occlusion at multiple time points during the first year after UIA diagnosis and studied predictors of QoL outcomes. Methods: We performed a prospective cohort study in patients ≥18 years old with a newly diagnosed UIA in two tertiary referral centers in the Netherlands between 2017 and 2019. Patients were sent QoL questionnaires at 7 (aneurysm occlusion) or 5 (no occlusion) moments during the first year after diagnosis. We collected baseline data on patient and aneurysm characteristics, passive coping style (Utrecht Coping List), occlusion modality, and neurological complications. We assessed health-related QoL (HRQoL) with the EuroQol 5-dimensions (EQ-5D), emotional functioning with the Hospital Anxiety and Depression Scale (HADS), and restrictions in daily activities with the Utrecht Scale for Evaluation of Rehabilitation-Participation (USER-P). We used a linear mixed effects model to assess the course of QoL over time and to explore predictors of QoL outcomes. Results: Of 153 eligible patients, 99 (65%) participated, of whom 30/99 (30%) underwent preventive occlusion. Patients undergoing occlusion reported higher baseline levels of passive coping, anxiety and depression, and restrictions than patients without occlusion. During recovery after occlusion, patients reported more restrictions compared to baseline (adjusted USER-P decrease one-month post-occlusion: -12.8 (95%CI:-23.8- -1.9). HRQoL and emotional functioning gradually improved after occlusion (EQ-5D increase at one-year: 8.6 (95%CI:0.1-17.0) and HADS decrease at one-year: -5.4 (95%CI:-9.4- -1.5)). In patients without occlusion, the largest HRQoL improvement occurred directly after visiting the outpatient aneurysm clinic (EQ-5D increase: 9.2 (95%CI:5.5-12.8)). At one-year, QoL outcomes were comparable in patients with and without occlusion. Factors associated with worse QoL outcomes were a passive coping style in all patients, complications in patients with occlusion and higher rupture risks in patients without occlusion. Conclusions: After UIA diagnosis, QoL improves gradually after preventive occlusion and directly after counselling at the outpatient clinic in patients without occlusion, resulting in comparable one-year QoL outcomes. A passive coping style is an important predictor of poor QoL outcomes in all UIA patients.

12 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
WSWouter M. Sluis
Wouter M. Sluis
MLMarijke Linschoten
Marijke Linschoten
JBJulie E. Buijs
Julie E. Buijs
JBJ. Matthijs Biesbroek
J. Matthijs Biesbroek
HHHeleen M. Den Hertog
Heleen M. Den Hertog
AAAnnemijn M. Algra
Annemijn M. Algra
Background and purpose: The frequency of ischemic stroke in patients with COVID-19 varies in the current literature, and risk factors are unknown. We assessed the incidence, risk factors, and outcomes of acute ischemic stroke in hospitalized patients with COVID-19. Methods: We included patients with a laboratory confirmed SARS-CoV-2 infection admitted in 16 hospitals participating in the international CAPACITY-COVID registry between March 1 st and August 1 st , 2020. Patients were screened for the occurrence of acute ischemic stroke. We calculated the cumulative incidence of ischemic stroke and compared risk factors, cardiovascular complications, and in-hospital mortality in patients with and without ischemic stroke. Results: We included 2147 patients with COVID-19, of whom 586 (27.3%) needed treatment at an intensive care unit (ICU). Thirty-eight patients (1.8%) had an ischemic stroke. Patients with stroke were older, but did not differ in sex or cardiovascular risk factors. Median time between onset of COVID-19 symptoms and diagnosis of stroke was two weeks. The incidence of ischemic stroke was higher among patients who were treated at an ICU (16/586; 2.7% versus 22/1561; 1.4%; p=0.039). Pulmonary embolism was more common in patients with (8/38; 21.1%) than in those without stroke (160/2109; 7.6%; adjusted RR: 2.08; 95%CI:1.52-2.84). Twenty-seven patients with ischemic stroke (71.1%) died during admission or were functional dependent at discharge and in-hospital mortality. Patients with ischemic stroke were at a higher risk of in-hospital mortality (adjusted RR 1.56; 95%CI:1.13-2.15) than patients without stroke. Conclusions: In this multicenter cohort study, the cumulative incidence of acute ischemic stroke in hospitalized patients with COVID-19 was approximately 2%, with a higher risk in patients treated at an ICU. The majority of stroke patients had a poor outcome. The association between ischemic stroke and pulmonary embolism warrants further investigation.